Skip to content

Neuroplasticity research: what the evidence shows

The brain's capacity to reorganize, a leading candidate mechanism for the lasting effects of psychedelics and learning.

State of the evidence

Synthesized

Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Neuroplasticity, neural plasticity, brain plasticity, synaptic plasticity, neurogenesis, then ranked by relevance.

The research consistently points toward neuroplasticity as a real, experience- and drug-dependent process: meditation practice is associated with thicker cortex and altered attention networks, while psychedelics and ketamine rapidly promote dendritic growth, spine formation, and synaptic signaling in prefrontal and hippocampal regions. Human imaging studies also show lasting functional changes (increased network integration, altered amygdala reactivity, greater cognitive flexibility) after psilocybin, though these are small, mostly open-label cohorts. The main caveats are that much of the mechanistic evidence comes from animal and in vitro work, human samples are small, and durability beyond weeks to a month is largely unestablished.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Meditation experience is associated with increased cortical thickness 2005 observational cohort 20 Supports Meditators showed greater cortical thickness in prefrontal cortex and right anterior insula than controls, with prefrontal differences largest in older participants and thickness in two regions correlating with meditation experience.
Psychedelics Promote Structural and Functional Neural Plasticity 2018 laboratory study Supports Serotonergic psychedelics increased neuritogenesis and spinogenesis and raised synapse number and function, apparently via TrkB, mTOR, and 5-HT2A signaling.
Neural correlates of attentional expertise in long-term meditation practitioners 2007 observational cohort Supports Sustained-attention activation followed an inverted U with expertise, and experts showed less activation in discursive-thought regions and more in response-inhibition regions during distracters, with correlations to practice hours suggesting plasticity.
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. 2017 observational cohort 19 Supports After psilocybin, amygdala blood flow decreased and default-mode network connectivity increased, with specific connectivity changes predicting clinical response at five weeks.
Functional Reorganization of the Default Mode Network across Chronic Pain Conditions 2014 observational cohort Mixed Chronic pain was associated with decreased medial prefrontal connectivity to posterior default-mode regions but increased connectivity to insula proportional to pain intensity, alongside altered oscillatory dynamics.
Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors 2023 experimental study Supports Intracellular 5-HT2A receptors, rather than cell-surface ones, mediated psychedelic-induced plasticity, explaining why serotonin does not engage the same mechanism.
Psychedelics promote plasticity by directly binding to BDNF receptor TrkB 2023 experimental study Supports LSD and psilocin bound TrkB with high affinity and produced neurotrophic, plasticity, and antidepressant-like effects dependent on TrkB but independent of 5-HT2A activation.
Increased global integration in the brain after psilocybin therapy for depression. 2022 open-label trial and double-blind RCT Supports In both trials the antidepressant response to psilocybin was rapid and sustained and correlated with decreased brain network modularity, suggesting greater global network integration.
Cognitive-Affective Neural Plasticity following Active-Controlled Mindfulness Intervention 2012 randomized controlled trial Supports Mindfulness training reduced affective Stroop conflict and increased dorsolateral prefrontal responses during executive processing, with the most practice linked to better response inhibition and greater anterior cingulate, medial prefrontal, and insular recruitment.
Emotions and brain function are altered up to one month after a single high dose of psilocybin. 2020 open-label pilot study 12 Supports One week after psilocybin, negative affect and amygdala reactivity were reduced and positive affect and prefrontal responses increased; at one month positive affect remained elevated, trait anxiety was lower, and resting-state connectivity was increased.
A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists 2012 review Supports Ketamine rapidly induced synaptogenesis and spine formation in prefrontal cortex via mTOR signaling, reversing stress-induced atrophy and corresponding to rapid antidepressant behavior.
Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. 2021 open-label study 24 Mixed Psilocybin therapy increased cognitive flexibility for at least four weeks, but greater increases in anterior cingulate-posterior cingulate dynamic connectivity were associated with less improvement in cognitive flexibility.
LSD-induced entropic brain activity predicts subsequent personality change. 2016 placebo-controlled study 19 Supports LSD increased global brain entropy, and these increases predicted enduring rises in trait openness two weeks later, especially during music listening and with ego dissolution.
Towards an understanding of psychedelic-induced neuroplasticity. 2023 review Supports Reviews evidence that psychedelics promote dendritogenesis, synaptogenesis, neurogenesis, and plasticity-related gene expression, particularly in prefrontal cortex and hippocampus, and discusses dose and duration questions.
Effective connectivity changes in LSD-induced altered states of consciousness in humans. 2019 double-blind randomized placebo-controlled cross-over study 25 Supports LSD altered effective connectivity within cortico-striato-thalamo-cortical pathways, increasing thalamus-to-posterior-cingulate connectivity via 5-HT2A activation and decreasing ventral-striatum-to-thalamus connectivity independently of it.
Ketamine administration reduced conditioned defensive behaviour and upregulated protein expression associated with neuroplasticity in a planarian model of aversive memory reactivation. 2026 preclinical experimental study 15 Supports Ketamine reduced defensive behaviors during aversive memory reactivation and was accompanied by enrichment of pathways linked to rapid neuronal growth and synaptic plasticity.
Psilocybin enhances conditioned place preference learning in planarians. 2026 controlled laboratory experiment Supports A single psilocybin exposure enhanced conditioned place preference learning relative to controls, with effects persisting at least six days, interpreted as support for conserved serotonergic plasticity mechanisms.
Ayahuasca Impairs Fear Memory Reconsolidation and Promotes Rapid Structural Plasticity in the Hippocampus and Prelimbic Cortex. 2026 controlled animal experiment Supports Ayahuasca around fear memory retrieval reduced freezing and increased dendritic spine density in hippocampal CA1, CA3, dentate gyrus, and prelimbic cortex, without affecting adult hippocampal neurogenesis.
Extracellular flux analysis and proteomic profiling indicate ibogaine promotes synaptic plasticity and neural repair by a metabolic preconditioning mechanism 2026 preclinical experimental study Supports Ibogaine caused transient metabolic suppression followed by an energy rebound and time-dependent activation of synaptic plasticity and neural repair signaling, proposed as metabolic preconditioning.
The Role of Neuroplasticity in Well-Being 2026 theoretical Supports Argues that neuroplasticity offers a route to wellbeing through practices such as mindfulness, positive thinking, and cognitive reappraisal, citing default-mode network changes, improved prefrontal-limbic regulation, and increased cortical thickness.
Ketamine-enhanced psychotherapy for smoking cessation: A pilot study of feasibility, safety, and clinical outcomes. 2026 open-label pilot study 7 Supports Three weekly ketamine sessions with motivational enhancement therapy were feasible and well tolerated, with reduced cigarette consumption and craving but stable withdrawal and dependence severity.
5-HT2A receptor activation is dispensable for psilocybin-induced fear extinction and neuroplasticity in mice. 2026 controlled preclinical experiment Supports Psilocybin facilitated fear extinction and raised BDNF and doublecortin-positive cells even when 5-HT2A receptors were blocked, indicating these effects do not require 5-HT2A activation.
Botanical Context Biasing for Experience-Dependent Neuroplasticity: A Two-Timescale Hypothesis of Directional Reinforcement During Psilocybin-Induced Plasticity 2026 theoretical Unclear Proposes, as an untested hypothesis from uncontrolled observations, that companion botanicals co-formulated with psilocybin can bias the trajectory of the psychedelic state across tonic and phasic timescales.
Psilocybin and Chronic Neuropathic and Centralized Pain: Converging Mechanisms in Central Sensitization, Neuroplasticity, and Network Organization 2026 systematic review Mixed Preclinical results were mixed, including a rigorous null study, and human evidence was limited to one small open-label pilot plus case reports and surveys, judged insufficient to establish psilocybin as an analgesic.
860. Glutamatergic Signaling and Neuroplasticity in Mood Disorders: A Historical Perspective from Preclinical Discoveries to Clinical Translation 2026 narrative review Supports Argues that glutamatergic signaling links synaptic plasticity to mood disorder pathophysiology, with ketamine acting via NMDA blockade, AMPA throughput, and mTORC1/eIF4E-dependent synaptogenesis, and that mood disorders should be viewed as disorders of neuroplasticity.

Points of agreement

  • Multiple lines of evidence link serotonergic psychedelics and ketamine to rapid structural plasticity, including dendritic growth, spine formation, and synaptogenesis in prefrontal cortex and hippocampus.
  • Human imaging studies report lasting functional changes after psilocybin, including altered default-mode network connectivity, reduced amygdala reactivity, and increased network integration.
  • Meditation practice is associated with structural and functional brain differences in attention and interoceptive regions, with some effects scaling with practice experience.
  • Several studies implicate BDNF/TrkB, mTOR, and 5-HT2A signaling as mechanisms underlying drug-induced plasticity.
  • Plasticity-related changes are often linked to clinical or behavioral outcomes such as antidepressant response or cognitive flexibility.

Conflicts

  • Some work attributes psychedelic plasticity to 5-HT2A receptor activation, while other studies report plasticity and behavioral effects that persist when 5-HT2A is blocked or that depend on TrkB instead.
  • One study found greater anterior cingulate-posterior cingulate dynamic connectivity associated with less cognitive flexibility improvement, contrary to a simple more-connectivity-is-better reading.
  • Preclinical pain findings are mixed, with some studies reporting analgesic effects and at least one rigorous null study.
  • Ayahuasca increased spine density without affecting adult hippocampal neurogenesis, whereas other work emphasizes neurogenesis as a plasticity mechanism.

Gaps

  • Durability of structural and functional changes beyond weeks to a month is largely unestablished in humans.
  • Human samples are small and often open-label, limiting causal inference and blinding.
  • Dose-response relationships, including microdoses versus hallucinogenic doses, remain unresolved.
  • Most mechanistic evidence comes from rodents, planarians, or in vitro preparations, with unclear translation to humans.
  • Whether plasticity changes mediate clinical benefit, rather than merely accompany it, is not established.
  • Long-term safety and effects in healthy versus clinical populations are understudied.
Browse these studies in the library

Common questions

What does the research agree on about neuroplasticity?
  • Multiple lines of evidence link serotonergic psychedelics and ketamine to rapid structural plasticity, including dendritic growth, spine formation, and synaptogenesis in prefrontal cortex and hippocampus.
  • Human imaging studies report lasting functional changes after psilocybin, including altered default-mode network connectivity, reduced amygdala reactivity, and increased network integration.
  • Meditation practice is associated with structural and functional brain differences in attention and interoceptive regions, with some effects scaling with practice experience.
  • Several studies implicate BDNF/TrkB, mTOR, and 5-HT2A signaling as mechanisms underlying drug-induced plasticity.
  • Plasticity-related changes are often linked to clinical or behavioral outcomes such as antidepressant response or cognitive flexibility.
Where do studies on neuroplasticity conflict?
  • Some work attributes psychedelic plasticity to 5-HT2A receptor activation, while other studies report plasticity and behavioral effects that persist when 5-HT2A is blocked or that depend on TrkB instead.
  • One study found greater anterior cingulate-posterior cingulate dynamic connectivity associated with less cognitive flexibility improvement, contrary to a simple more-connectivity-is-better reading.
  • Preclinical pain findings are mixed, with some studies reporting analgesic effects and at least one rigorous null study.
  • Ayahuasca increased spine density without affecting adult hippocampal neurogenesis, whereas other work emphasizes neurogenesis as a plasticity mechanism.
What is still unknown about neuroplasticity?
  • Durability of structural and functional changes beyond weeks to a month is largely unestablished in humans.
  • Human samples are small and often open-label, limiting causal inference and blinding.
  • Dose-response relationships, including microdoses versus hallucinogenic doses, remain unresolved.
  • Most mechanistic evidence comes from rodents, planarians, or in vitro preparations, with unclear translation to humans.
  • Whether plasticity changes mediate clinical benefit, rather than merely accompany it, is not established.
  • Long-term safety and effects in healthy versus clinical populations are understudied.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Neuroplasticity, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Neuroplasticity or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

Latest monthly recap: September 2026 →

1,765 articles · 873 from the last two years · 39,628 participants across 250 studies reporting sample size

Common study designs

review 490 experimental study 108 observational cohort 71 randomized controlled trial 68 theoretical or philosophical paper 250

Research volume by year

Compare topics →

534 studies whose primary subject is neuroplasticity since 2002

Studies about neuroplasticity per year, 2002 to 2026, peaking at 120 in 2025 Bar chart: one bar per year, taller where more studies were published that year. 0 100 200 2005 2010 2015 2020 2025
2026 is partial
Show the numbers
Studies about neuroplasticity per year, 2002 to 2026, peaking at 120 in 2025
Year Studies
2002 1
2003 1
2004 1
2005 2
2006 1
2007 1
2008 1
2009 7
2010 5
2011 4
2012 6
2013 3
2014 13
2015 4
2016 15
2017 18
2018 22
2019 13
2020 16
2021 32
2022 24
2023 45
2024 60
2025 120
2026 119

Research

Synthesize the evidence → Search all →

Ketamine administration reduced conditioned defensive behaviour and upregulated protein expression associated with neuroplasticity in a planarian model of aversive memory reactivation.

Progress in neuro-psychopharmacology & biological psychiatry October 17, 2026 Fionnghuala L J James, Sayed K Ahamed, Cheng-I Yang et al.

Traumatic memories that are resistant to modification or extinction are a characteristic feature of post-traumatic stress disorder (PTSD). The process of fear memory reconsolidation has been identified as a potential therapeutic target for the treatment of PTSD. Ketamine, an NMDA receptor antagonist with dissociative properties, has been identified as a drug with high therapeutic potential for...

DOI: 10.1016/j.pnpbp.2026.111979 (opens in new tab) Full text (opens in new tab) Ketamine Neuroplasticity PTSD Planaria +2

Extracellular flux analysis and proteomic profiling indicate ibogaine promotes synaptic plasticity and neural repair by a metabolic preconditioning mechanism

bioRxiv (Cold Spring Harbor Laboratory) October 2, 2026 Madison J Oulton, Gracious D. S. Kasheke, Kelly A. Meaney et al. preprint

We have examined how ibogaine may enhance synaptic plasticity and neural repair. Extracellular efflux analysis showed that ibogaine (3, 10 or 30 μM) produced a rapid (<5 minutes) and concentration-dependent suppression of mitochondrial function and glycolysis in mouse cortical neurons. Cell-based imaging demonstrated this metabolic inhibition was preceded by an elevation of the mitochondrial...

DOI: 10.64898/2026.09.29.755437 (opens in new tab) Full text (opens in new tab)

The Role of Neuroplasticity in Well-Being

September 25, 2026 Apoorav Sharma, Lovleen Marwaha

The neuroplasticity, the natural ability of the brain to change its structure and its functioning based on experience has become a unifying concept of neuroscience, psychology and even clinical practise. This chapter discusses the potential of neuroplasticity in achieving psychological wellbeing through deliberate cognitive and behavioral activities, including mindfulness, positive thinking,...

DOI: 10.4018/979-8-3373-7401-7.ch002 (opens in new tab)

5-HT2A receptor activation is dispensable for psilocybin-induced fear extinction and neuroplasticity in mice.

Chinese medical journal September 15, 2026 Yingjie Du, Xiangting Zhao, Quan Chen et al.

Psilocybin facilitates fear extinction in rodents, but its clinical utility is hampered by 5-hydroxytryptamine (5-HT) 2A-receptor-mediated hallucinogenic effects. This study aimed to explore whether 5-HT2A receptor is obligatory for psilocybin's fear extinction and neuroplasticity effect. Male C57BL/6J mice underwent auditory-cue fear conditioning. Ketanserin (5-HT2A/2C antagonist) or MDL100907...

DOI: 10.1097/cm9.0000000000004350 (opens in new tab) Full text (opens in new tab) Psilocybin Fear extinction Hallucinogenic effects Medial prefrontal cortex +2

Botanical Context Biasing for Experience-Dependent Neuroplasticity: A Two-Timescale Hypothesis of Directional Reinforcement During Psilocybin-Induced Plasticity

Zenodo (CERN European Organization for Nuclear Research) September 14, 2026 Shaun Robinson preprint

Psilocybin and related psychedelics can induce transient states of increased neural variability, context sensitivity, and plasticity-associated signaling. We hypothesize that selected companion botanicals can be composed with psilocybin to create a reproducible physiological and experiential lens, a botanical context, that biases the qualitative trajectory of the psychedelic state without...

DOI: 10.5281/zenodo.22758088 (opens in new tab)

Psilocybin and Chronic Neuropathic and Centralized Pain: Converging Mechanisms in Central Sensitization, Neuroplasticity, and Network Organization

Anesthesia Research September 11, 2026 M. S. Neves, C. T. P. Gusmão, Raimundo Chiyo et al.

Background/Objectives: Neuropathic and chronic centralized pain disorders remain difficult to treat because they involve central sensitization, maladaptive neuroplasticity, neuroimmune activation, affective amplification, and large-scale network dysfunction. Psilocybin, a serotonergic psychedelic acting primarily through 5-HT2A receptor agonism, has emerged as a candidate modulator of chronic...

DOI: 10.3390/anesthres3030026 (opens in new tab) Full text (opens in new tab)

515. Influence of the context of administration on 5-MeO-DMT-promoted antidepressant-like effects and neuroplasticity

The International Journal of Neuropsychopharmacology September 9, 2026 Romain Hacquet, P Pantiya, G Gotti et al.

Abstract Background Psychedelics such as psilocybin have demonstrated rapid and sustained antidepressant effects in humans, particularly when administered in carefully designed therapeutic environments (Borkel et al., 2024; Carhart-Harris et al., 2021). DMT and 5-MeO-DMT, distinguished by their brief duration of psychedelic effects, have also shown encouraging preliminary outcomes in depressive...

DOI: 10.1093/ijnp/pyag040.084 (opens in new tab)

753. The Mechanism of Ketamine’s Anti-Suicidal Action: From Glutamatergic Surge to Neuroplasticity via the Opioid-Attachment Interface

The International Journal of Neuropsychopharmacology September 9, 2026 A Solomon, Y Domany

Abstract Background A critical gap exists in understanding the biological mechanism linking ketamine’s rapid anti-suicidal effects to the Interpersonal Theory of Suicide (IPTS). While the "Kinetic Mismatch" between acute relief and delayed synaptogenesis is well-known, current models overlook how ketamine modulates “Thwarted Belongingness” (a core IPTS pillar) and the attachment anxiety that...

DOI: 10.1093/ijnp/pyag040.400 (opens in new tab)

860. Glutamatergic Signaling and Neuroplasticity in Mood Disorders: A Historical Perspective from Preclinical Discoveries to Clinical Translation

The International Journal of Neuropsychopharmacology September 9, 2026 Gabriella Gobbi

Abstract Background While the monoaminergic hypothesis has long dominated the treatment of mood disorders, its limitations have prompted the exploration of alternative mechanisms. Early work by Skolnick et al. (1996) demonstrated that chronic antidepressant treatment induces adaptive changes in N-methyl-D-aspartate (NMDA) receptors, suggesting glutamatergic signaling as a convergent pathway in...

DOI: 10.1093/ijnp/pyag040.515 (opens in new tab)

The mPFC-reuniens-hippocampus pathway links brain circuitry and neural plasticity in antidepressant response

Nature Communications September 1, 2026 Maxime Veleanu, Louise E. Schuberth, Antje Kilias et al.

The pathophysiology of depression involves multiple biological processes, including circuit dysfunction and impaired neuroplasticity, yet an integrative view linking these processes remains elusive. Here, we identify a convergent circuit for antidepressant response and plasticity modulation. We demonstrate that chemogenetic activation of the infralimbic cortex (IL) exerts rapid...

DOI: 10.1038/s41467-026-77248-y (opens in new tab) Full text (opens in new tab)

Clinical trials

All Neuroplasticity trials →